532 related articles for article (PubMed ID: 27175028)
1. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
2. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
3. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
4. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
5. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
6. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
8. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Alvarez-Larrán A; Cervantes F; Pereira A; Arellano-Rodrigo E; Pérez-Andreu V; Hernández-Boluda JC; Ayats R; Salvador C; Muntañola A; Bellosillo B; Vicente V; Hernández-Nieto L; Burgaleta C; Xicoy B; Besses C
Blood; 2010 Aug; 116(8):1205-10; quiz 1387. PubMed ID: 20508163
[TBL] [Abstract][Full Text] [Related]
9. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
11. One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
Gangat N; Karrar O; Al-Kali A; Begna KH; Elliott MA; Wolanskyj-Spinner AP; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2024 Jan; 14(1):11. PubMed ID: 38238303
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
[TBL] [Abstract][Full Text] [Related]
13. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
15. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract][Full Text] [Related]
17. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
Loscocco GG; Gesullo F; Capecchi G; Atanasio A; Maccari C; Mannelli F; Vannucchi AM; Guglielmelli P
Blood Cancer J; 2024 Jan; 14(1):10. PubMed ID: 38238287
[TBL] [Abstract][Full Text] [Related]
18. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
[No Abstract] [Full Text] [Related]
19. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
20. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
